控制人类白血病干细胞和治疗耐药性的表观遗传机制
Sumiko Takao1,2, Victor Morell1,2, Masahiro Uni1,2
1Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature communications
|April 3, 2025
概括
癌症干细胞驱动白血病的发病和耐治疗性. 罕见的静止细胞群,对于白血病的传播至关重要,可以识别和针对新的治疗方法.
科学领域:
- 在瘤学瘤学.
- 干细胞生物学 干细胞生物学
- 基因组学就是基因组学.
背景情况:
- 癌症干细胞 (CSCs) 对于启动和抵抗急性髓性白血病 (AML) 等癌症的治疗至关重要.
- 识别和准CSC仍然是癌症治疗中的一个重大挑战.
- 高风险白血病亚型,如MLL和NUP98重组的亚型,存在独特的治疗障碍.
研究的目的:
- 识别和描述负责急性髓性白血病 (AML) 传播的特定细胞群.
- 了解白血病干细胞 (LSC) 静止的基础机制及其在治疗耐药性中的作用.
- 探索基于其独特的生物特性来隔离和准LSC的新策略.
主要方法:
- 包括高风险标本在内的各种人类白血病样本的功能性基因组分析.
- 在体内进行标签追踪实验,以识别和追踪白血病传播细胞.
- 在静止标签保留细胞 (LRCs) 中分析染色素和基因表达动态.
- 研究AP-1/ETS转录因子网络,特别是JUN在LSC静止中的作用.
主要成果:
- 白血病的传播是由一个罕见的,静止的标签保留细胞 (LRC) 群体驱动的,不能通过当前的标记物识别.
- AML静止是可逆的,保持遗传和表观遗传的完整性.
- LRC静止的特点是特定的染色质和基因表达模式,由AP-1/ETS网络调节.
- 对于LRC静止来说,JUN是必不可少的,足够的,并且与患者的持久性和化疗耐药性相关.
结论:
- 一个独特的静止的LRC群体调解了人类白血病的传播和治疗耐药性.
- 表观遗传可塑性和特定转录因子网络 (AP-1/ETS,JUN) 控制了LSC静止.
- 这些发现使LSCs的未来隔离成为可能,并为AML治疗和控制提供了新的治疗点.
相关概念视频
01:21Lineage Commitment
2.9K
Commitment is the process whereby stem cells:
2.9K
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:19Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K